Skip to main content

Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)

1
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Innoviva Specialty Therapeutics
2 programs
1
Sulbactam 25mg/kg -Durlobactam 25mg/kgPhase 11 trial
Non-interventionalN/A1 trial
Active Trials
NCT06746883Recruiting100Est. Jan 2029
NCT06801223Recruiting48Est. May 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
Innoviva Specialty TherapeuticsSulbactam 25mg/kg -Durlobactam 25mg/kg
Innoviva Specialty TherapeuticsNon-interventional

Clinical Trials (2)

Total enrollment: 148 patients across 2 trials

NCT06801223Innoviva Specialty TherapeuticsSulbactam 25mg/kg -Durlobactam 25mg/kg

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Start: Oct 2026Est. completion: May 202848 patients
Phase 1Recruiting
NCT06746883Innoviva Specialty TherapeuticsNon-interventional

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

Start: Apr 2025Est. completion: Jan 2029100 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 148 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.